retatrutide phase 2 trial obesity nejm 2023 (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 🧬 R3TA is a next-generation

This article covers the pharmacological half-life of the .25 mg dose, the factors that influence its clearance, and what you can expect as the medication leaves your system

Preparing for your Phoenix peptide therapy journey Maximize your results by preparing appropriately before beginning peptide therapy

In the trials reporting discontinuation because of any adverse events and those specifically due to gastrointestinal side effects, the latter were responsible for approximately one-half of the withdrawals

Sugary drinks, creamy coffees and calorie-heavy smoothies can quickly take up a disproportionate share of daily intake without providing lasting satisfaction

Much less clear at this time is whether that benefit would accrue to those for whom these drugs are not currently indicated

[DOI] [PubMed] [Google Scholar] 316.Verma S, et al